Endoradiotherapy in cancer treatment--basic concepts and future trends.
Endoradiotherapy represents an alternative therapeutic method in cancer treatment with advantageous features compared to chemotherapy and radiation therapy. Intelligent dose delivery concepts using small drugs, peptides or antibodies as radionuclide carriers enable the verification of a selective accumulation in the tumour lesion and to reduce radiation toxicity for the peripheral organs. The development of endoradiotherapeutic agents, especially chelator-conjugated biomolecules, for example ibritumomab tiuxetan or DOTATOC, gains importance due to the stable complexation of versatile radiometals, such as (90)Y or (177)Lu. The rational design of novel target binding sides and their grafting into a drug scaffold is a highly promising strategy, which may promote further implication in endoradiotherapy. This review highlights the basic concepts of endoradiotherapy and discusses the potential of targeted therapy and the properties of energy-rich particles emitted by radionuclides for tumour therapy.
Zoller
Frederic
F
Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Centre, INF 280, 69120 Heidelberg, Germany.
Eisenhut
Michael
M
Haberkorn
Uwe
U
Mier
Walter
W
D000818:Animals; D000906:Antibodies / Q000627:therapeutic use; D001665:Binding Sites; D006801:Humans; D009369:Neoplasms / Q000276:immunology / Q000532:radiotherapy*; D010455:Peptides / Q000627:therapeutic use; D016499:Radioimmunotherapy / Q000379:methods*; D011868:Radioisotopes / Q000627:therapeutic use; D019275:Radiopharmaceuticals / Q000627:therapeutic use*; D011879:Radiotherapy Dosage; D018000:Receptors, Peptide / Q000378:metabolism / Q000528:radiation effects
D000906:Antibodies; D010455:Peptides; D011868:Radioisotopes; D019275:Radiopharmaceuticals; D018000:Receptors, Peptide